Ga-68 Dolacga PET Scan in HCC Under RFA

Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL · Jan 19, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new type of PET scan called Ga-68 Dolacga to see how well it can help doctors assess the response to treatment and changes in liver function for patients with early-stage liver cancer, known as hepatocellular carcinoma (HCC), who are receiving a treatment called radiofrequency ablation (RFA). The trial aims to find out how effective this PET scan is compared to traditional CT scans and how its results relate to patient outcomes, like liver function and the chance of the cancer coming back.

To participate in this trial, patients should be adults aged 18 or older with specific types of early-stage liver cancer, such as a single tumor smaller than 2 cm or a few tumors that are each smaller than 3 cm. Participants will undergo both the Ga-68 Dolacga PET scans and CT scans before and one month after their RFA treatment, and then they will be monitored every three months afterward. This trial is not yet recruiting participants, but it will provide important insights into the best ways to monitor liver cancer treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Patients with hepatocellular carcinoma (BCLC stage 0 and stage A) eligible for radiofrequency ablation (RFA) treatment exhibit the following characteristics:
• • 1. A single liver tumor, ≤ 2 cm, classified as BCLC stage 0 (very early stage).
• • 2. Tumors ≤ 3 in number, each ≤ 3 cm, or a single tumor ≤ 5 cm, classified as BCLC stage A (early stage) liver cancer.
• • 3. ECOG performance status of 0.
• • 4. Age ≥ 18 years.
• Exclusion Criteria:
• * Intermediate (BCLC B stage) and advanced (BCLC C stage) liver cancer patients:
• • 1. A single tumor \> 5 cm, or multiple tumors \> 3 cm.
• • 2. Diffuse hepatocellular carcinoma.
• • 3. Vascular invasion (e.g., portal vein obstruction).
• • 4. Extrahepatic tumor spread.
• * Early-stage liver cancer (BCLC A stage):
• • 1. Contraindications for radiofrequency ablation (RFA).
• • 2. Target lesions previously treated with local therapies, including surgical resection, percutaneous ethanol injection (PEI), or liver transplantation.